natgillin/translations-raw huggingface dataset:
Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to < 18 years and weighing at least 40 kg without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l (see section 4.2).
Stoga se isto doziranje od jedanput na dan može primijeniti kod adolescenata koji su prethodno liječeni u dobi od 12 do < 18 godina s težinom najmanje 40 kg, koji nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM)* a imaju plazmatsku HIV-1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
In the 96 week analysis, the safety profile of darunavir/ ritonavir 800/100 mg once daily in treatmentnaïve subjects was similar to that seen with darunavir/ ritonavir 600/100 mg twice daily in treatmentexperienced subjects except for nausea which was observed more frequently in treatment-naïve subjects.
U 96 tjednoj analizi, sigurnosni profil primjene darunavira/ritonavira od 800/100 mg jedanput na dan u prethodno neliječenih ispitanika bio je sličan profilu primjene darunavira/ritonavira od 600/100 mg dva puta na dan u prethodno liječenih ispitanika, osim mučnine koja je češće opažena u prethodno neliječenih ispitanika.
Postpartum (6-12 weeks) (n=6)
Postpartalno razdoblje (6 12 tjedana) (n=6)
Darunavir must be taken in combination with a low dose of cobicistat or ritonavir and other anti-HIV medicines.
Darunavir se mora uzimati u kombinaciji s niskom dozom kobicistata ili ritonavira i drugim lijekovima protiv HIV-a.
EXP Once opened, use within 90 days
Nakon otvaranja iskoristiti u roku od 90 dana
HIV RNA < 50 copies/ml a
HIV RNK < 50 kopija/ml a c c
Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).
Darunavir, primijenjen istodobno s niskom dozom ritonavira, indiciran je u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje bolesnika koji su inficirani virusom humane imunodeficijencije (HIV-1) (vidjeti dio 4.2).
6/l, a regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used.
6/l, može se koristiti režim od 800 mg jedanput na dan s ritonavirom od 100 mg jedanput na dan, uzeto s hranom.
In women receiving darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 33%, 31% and 30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum.
U žena koje su primale darunavir/ritonavir 800/100 mg jedanput dnevno tijekom drugog tromjesečja trudnoće, srednje intra-individualne vrijednosti za ukupni darunavir Cmax, AUC24h i Cmin bile su Cmax, 33%, 31% odnosno 30% niže, uspoređujući s postpartalnim razdobljem; tijekom trećeg tromjesečja trudnoće, ukupne vrijednosti za darunavir Cmax, AUC24h i Cmin bile su 29%, 32% odnosno 50% niže, uspoređujući s postpartalnim razdobljem.
Several of the interaction studies (indicated by in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Nekoliko ispitivanja interakcija (označeno s u tablici ispod) provodilo se s nižom dozom darunavira od preporučene, ili uz različit režim doziranja (vidjeti dio 4.2 Doziranje).
administering darunavir with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered.
Preporučuje se kliničko praćenje kada se darunavir primjenjuje istodobno s tim sedativima/hipnoticima i u obzir treba uzeti nižu dozu sedativa/hipnotika.
How to take Darunavir Mylan
Kako uzimati lijek Darunavir Mylan
The recommended dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted darunavir.
Preporučena doza emtricitabin/tenofoviralafenamida kada se uzima s pojačanim darunavirom je 200/10 mg jedanput na dan.
A once daily dose regimen of darunavir taken with ritonavir taken with food may be used in patients with prior exposure to antiretroviral medicinal products but without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Režim doziranja lijeka darunavir jedanput na dan s ritonavirom uzeto s hranom, može se primijeniti u bolesnika koji su prethodno bili izloženi antiretrovirusnim lijekovima, ali nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM)* i koji imaju plazmatsku HIV-1 RNK < 100 000 kopija/ml i broj CD4+ stanica  100 stanica x 10
Rare conjunctival hyperaemia, dry eye visual disturbance
Poremećaji oka manje često rijetko konjunktivalna hiperemija, suho oko poremećaj vida
Recommended dose for treatment-naïve paediatric patients (3 to 17 years) with darunavir tablets and ritonavir a
Preporučena doza tableta darunavira i ritonaviraa za pedijatrijske bolesnike (od 3 do 17 godina)
Darunavir Mylan 75 mg film-coated tablets PVC/PE/PVDC-Al blister pack containing 480 tablets and 480x1 tablets.
Darunavir Mylan 75 mg filmom obložene tablete PVC/PE/PVDC-Al blister pakiranje koje sadrži 480 tableta i 480x1 tabletu.
Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% #darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
Nevirapin 200 mg dva puta na dan nevirapin AUC ↑ 27% nevirapin Cmin ↑ 47% nevirapin Cmax ↑ 18% # koncentracija darunavira bila je konzistentna s već postojećim podacima (↑ nevirapin zbog CYP3A inhibicije)
Darunavir Mylan 400 milligram and 800 milligram tablets are only to be used to construct the once daily 800 milligram regimen.
Tablete lijeka Darunavir Mylan od 400 miligrama i 800 miligrama treba primjenjivati samo da se dosegne režim doziranja od 800 miligrama jedanput na dan.
Patients with no/non-naïve use of ENFc
Bolesnici koji prije nisu liječeni s ENFd a
Etravirine 100 mg twice daily etravirine AUC ↓ 37% etravirine Cmin ↓ 49% etravirine Cmax ↓ 32% darunavir AUC ↑ 15% darunavir Cmin ↔ darunavir Cmax ↔
Etravirin 100 mg dva puta na dan etravirin AUC ↓ 37% etravirin Cmin ↓ 49% etravirin Cmax ↓ 32% darunavir AUC ↑ 15% darunavir Cmin ↔ darunavir Cmax ↔
If you notice within 6 hours, you must take the tablets immediately.
Ako primijetite da niste uzeli lijek unutar 6 sati, tablete morate uzeti odmah, uvijek s ritonavirom i hranom.
Boosted darunavir can be coadministered with proton pump inhibitors without dose adjustments.
Pojačani darunavir može biti primijenjen istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
Darunavir must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
Darunavir se uvijek mora primjenjivati peroralno s kobicistatom ili niskom dozom ritonavira kao farmakokinetičkim pojačivačem i u kombinaciji s drugim antiretrovirusnim lijekovima.
Darunavir Mylan contains the active substance darunavir.
Darunavir Mylan sadrži djelatnu tvar darunavir.
The combination of rifapentine and darunavir with concomitant low dose ritonavir is not recommended.
Kombinacija rifapentina i darunavira s istodobnom niskom dozom ritonavira se ne preporučuje.
Concominant use of everolimus or Irinotecan and darunavir coadministered with low dose ritonavir is not recommended.
Istodobno uzimanje everolimusa ili irinotekana i darunavira s niskom dozom ritonavira se ne preporučuje.
Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
Nevirapin 200 mg dva puta na dan nevirapin AUC ↑ 27% nevirapin Cmin ↑ 47% nevirapin Cmax ↑ 18% koncentracija darunavira bila je konzistentna s već postojećim podacima (↑ nevirapin zbog CYP3A inhibicije)
Concomitant use of darunavir with low dose ritonavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
Istodobna upotreba darunavira s niskom dozom ritonavira i elbasvira/grazoprevira je kontraindicirana (vidjeti dio 4.3).
OR - 800 milligram darunavir (2 tablets containing 400 milligram of darunavir or 1 tablet containing 800 milligram of darunavir) together with 100 milligram ritonavir once daily.
ILI - 800 miligrama darunavira (2 tablete koje sadrže 400 miligrama darunavira ili 1 tableta koja sadrži 800 miligrama darunavira) zajedno sa 100 miligrama ritonavira jedanput na dan.
Darunavir Mylan 75 mg film-coated tablets Each film-coated tablet contains 75 mg of darunavir.
Darunavir Mylan 75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg darunavira.
With baseline CD4+ cell count ≥ 200
S početnim brojem CD4+ stanica < 200 S početnim brojem CD4+ stanica ≥ 200
Cold form PVC/Al/OPA-Al blister pack containing 240 tablets and 240x1 tablets.
Hladno oblikovano PVC/Al/OPA-Al blister pakiranje koje sadrži 240 tableta i 240x1 tabletu.
Boosted darunavir can be used with these NRTIs without dose adjustment.
Pojačani darunavir može se primijeniti s ovim NRTI lijekovima bez prilagodbe doze.
Dose for adults who have taken antiretroviral medicines before (your doctor will determine this) The dose is either: - 600 milligram darunavir (2 tablets containing 300 milligram of darunavir or 1 tablet containing 600 milligram of darunavir) together with 100 milligram ritonavir twice daily.
Doza za odrasle koji su već prije uzimali antiretrovirusne lijekove (to će odrediti Vaš liječnik) Doza je: - 600 miligrama darunavira (2 tablete koje sadrže 300 miligrama darunavira ili 1 tableta koja sadrži 600 miligrama darunavira) zajedno sa 100 miligrama ritonavira dva puta na dan.
With baseline HIV-RNA
S početnom HIV-RNK
Cold form PVC/Al/OPA-Al blister pack containing 480 tablets and 480x1 tablets.
Hladno oblikovano PVC/Al/OPA-Al blister pakiranje koje sadrži 480 tableta i 480x1 tabletu.
UROLOGICAL DRUGS Fesoterodine
UROLOŠKI LIJEKOVI Fesoterodin
Each film-coated tablet contains 75 mg of darunavir.
Jedna filmom obložena tableta sadrži 75 mg darunavira.
OR - 600 milligram darunavir (2 tablets containing 300 milligram of darunavir or 1 tablet containing 600 milligram of darunavir) together with 100 milligram ritonavir twice daily.
ILI - 600 miligrama darunavira (2 tablete koje sadrže 300 miligrama darunavira ili 1 tableta koja sadrži 600 miligrama darunavira) zajedno sa 100 miligrama ritonavira dva puta na dan.
Darunavir Mylan 150 mg film-coated tablets PVC/PE/PVDC-Al blister pack containing 240 tablets and 240x1 tablets.
Darunavir Mylan 150 mg filmom obložene tablete PVC/PE/PVDC-Al blister pakiranje koje sadrži 240 tableta i 240x1 tabletu.
Blister carton 30 film-coated tablets 60 film-coated tablets 120 film-coated tablets 120 x 1 film-coated tablets
Kutija za blistere 30 filmom obloženih tableta 60 filmom obloženih tableta 120 filmom obloženih tableta 120 x 1 filmom obložena tableta
Darunavir co-administered with low dose ritonavir can be coadministered with proton pump inhibitors without dose adjustments.
Darunavir primijenjen istodobno s niskom dozom ritonavira može biti primijenjen istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
ANTIBIOTIC Clarithromycin 500 mg twice daily clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% #darunavir AUC ↓ 13% darunavir Cmin ↑ 1% #darunavir Cmax ↓ 17% 14-OH-clarithromycin concentrations were not detectable when combined with darunavir/ritonavir.
ANTIBIOTICI Klaritromicin 500 mg dva puta na dan klaritromicin AUC ↑ 57% klaritromicin Cmin ↑ 174% klaritromicin Cmax ↑ 26% #darunavir AUC ↓ 13% darunavir Cmin ↑ 1% #darunavir Cmax ↓ 17% Koncentraciju 14-OH- klaritromicina nije bilo moguće odrediti kada se kombinirao s darunavirom/ritonavirom.
Vascular disorders Uncommon hypertension, flushing
Krvožilni poremećaji manje često hipertenzija, navale crvenila
You must eat a meal or a snack within 30 minutes prior to taking your darunavir and cobicistat or ritonavir.
Unutar 30 minuta prije uzimanja darunavira i kobicistata ili ritonavira morate pojesti obrok ili nešto prigristi.
Pharmacokinetic results of total darunavir after administration of darunavir/cobicistat 800/150 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy, and postpartum
Farmakinetički rezultati ukupnog darunavira nakon primjene darunavira/kobicistata 800/150 mg jedanput na dan kao dijela antiretrovirusnog režima, tijekom drugog tromjesečja trudnoće, trećeg tromjesečja trudnoće i u postpartalnom razdoblju
Outcomes at Week 48
Ishodi u 48. tjednu
Concomitant use of sildenafil or tadalafil for the treatment of pulmonary arterial hypertension and darunavir co-administered with low dose ritonavir may increase plasma concentrations of sildenafil or tadalafil.
Istodobna primjena sildenafila ili tadalafila za liječenje plućne arterijske hipertenzije i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati koncentracije sildenafila ili tadalafila u plazmi. (CYP3A inhibicija)
Concominant administration of darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Istodobna primjena darunavira s niskom dozom ritonavira i lurasidona, pimozida ili sertindola je kontraindicirana (vidjeti dio 4.3).
Boosted darunavir with triazolam or oral midazolam is contraindicated (see section 4.3)
Pojačani darunavir s triazolamom ili peroralnim midazolamom je kontraindicirana (vidjeti dio 4.3)
Rare myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase musculoskeletal stiffness, arthritis, joint stiffness
Poremećaji mišićno-koštanog sustava i vezivnog tkiva manje često rijetko mialgija, osteonekroza, mišićni spazmi, mišićna slabost, artralgija, bol u ekstremitetima, osteoporoza, povišena kreatin-fosfokinaza u krvi mišićno-koštana ukočenost, artritis, ukočenost zglobova
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with boosted darunavir is required.
Ako je potrebno liječenje pojačanim darunavirom, preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Efavirenz in combination with darunavir/ritonavir 800/100 mg once daily may result in suboptimal darunavir Cmin.
Efavirenz u kombinaciji s lijekom darunavir/ritonavir od 800/100 mg jedanput na dan može rezultirati suboptimalnim vrijednostima Cmin darunavira.
Boosted darunavir and rilpivirine can be used without dose adjustments.
Pojačani darunavir i rilpivirin mogu se primijeniti bez prilagodbe doze.
480 film-coated tablets
Filmom obložena tableta 480 filmom obloženih tableta
HIV-1 RNA < 50 copies/ml c
HIV-1 RNK < 50 kopija/mla
Each tablet contains 150 milligram of darunavir.
Jedna tableta sadrži 150 miligrama darunavira.
Boosted darunavir may increase antifungal plasma concentrations and posaconazole, isavuconazole, itraconazole or fluconazole may increase darunavir concentrations.
Pojačani darunavir može povećati koncentracije antifungika u plazmi, a posakonazol, izavukonazol, itrakonazol ili flukonazol mogu povećati koncentracije darunavira. (CYP3A inhibicija i/ili P-gp inhibicija)
Concentrations of voriconazole may increase or decrease when coadministered with darunavir coadministered with cobicistat.
Koncentracije vorikonazola mogu se povećati ili smanjiti kada se istodobno primijenjuje s darunavirom istodobno primijenjenim s kobicistatom. (inhibicija CYP450 enzima)
Not known rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation
Poremećaji kože i potkožnog tkiva često manje često rijetko nepoznato osip (uključujući makularni, makulopapularni, papularni, eritematozni i osip koji svrbi), pruritus angioedem, generalizirani osip, alergijski dermatitis, urtikarija, ekcem, eritem, hiperhidroza, noćna znojenja, alopecija, akne, suha koža, pigmentacija noktiju
Uncommon diarrhoea, nausea vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, pancreatic enzymes increased pancreatitis acute
Poremećaji probavnog sustava vrlo često često manje često proljev, mučnina povraćanje, bol u abdomenu, distenzija abdomena, dispepsija, flatulencija, povišeni enzimi pankreasa akutni pankreatitis
Therefore, therapy with Darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir/cobicistat should be switched to an alternative regimen (see sections 4.2 and 4.6).
Stoga se liječenje lijekom Darunavir/kobicistatom ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja lijekom Darunavir/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.2 i 4.6).
Therefore, therapy with Darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir/cobicistat should be switched to an alternative regimen (see sections 4.4 and 4.6).
Stoga se liječenje lijekom Darunavir/kobicistatom ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja lijekom Darunavir/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.4 i 4.6).
Therapy with Darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with Darunavir/cobicistat should be switched to an alternative regimen (see sections 4.2 and 4.4).
Liječenje lijekom Darunavir/kobicistatom se ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja lijekom Darunavir/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.2 i 4.4).
HDPE bottle pack with a PP screw cap containing 60 and 240 tablets.
Boca od polietilena visoke gustoće (HDPE) s navojnim čepom od polipropilena koja sadrži 60 i 240 tableta.
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir used in combination with cobicistat or low dose ritonavir and patients should be monitored during treatment.
Prije početka terapije s darunavirom koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira, moraju se provesti odgovarajuća laboratorijska ispitivanja, te se bolesnike mora pratiti tijekom liječenja.
and who have plasma HIV-1 RNA < 100,000
(DRV-RAM) i koji imaju plazmatsku koncentraciju HIV-1 RNK < 100 000 kopija/ml i broj
Co-administration with the combination product lopinavir/ritonavir (see section 4.5).
Istodobna primjena s kombinacijom lijekova lopinavir/ritonavir (vidjeti dio 4.5).
Based on theoretical considerations darunavir is expected to increase alfuzosin plasma concentrations.
Na temelju teorijskih razmatranja očekuje se da će darunavir povećati koncentraciju alfuzozina u plazmi. (inhibicija CYP3A)
Tell your doctor if you take: - Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
Obavijestite liječnika ako uzimate: - amlodipin, diltiazem, dizopiramid, karvedilol, felodipin, flekainid, lidokain, metoprolol, meksiletin, nifedipin, nikardipin, propafenon, timolol, verapamil (za bolest srca), jer se terapijski učinak ili nuspojave tih lijekova mogu pojačati. - apiksaban, edoksaban, rivaroksaban, varfarin (smanjuje zgrušavanje krvi), jer terapijski učinak ili nuspojave mogu biti izmijenjene; liječnik će Vam možda htjeti provjeriti krvnu sliku.
- high blood pressure, flushing - red or dry eyes - fever, swelling of lower limbs due to fluids, malaise, irritability, pain - symptoms of infection, herpes simplex - erectile dysfunction, enlargement of breasts - sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive
- vrućica, oticanje nogu zbog nakupljanja tekućine, opća slabost, razdražljivost, bol - simptomi infekcije, herpes simpleks - erektilna disfunkcija, povećanje dojki - teškoće sa spavanjem, pospanost, depresija, tjeskoba, abnormalni snovi, smanjeni spolni nagon.
Darunavir Mylan contains sodium
Darunavir Mylan sadrži natrij
The combination of avanafil and darunavir with low dose ritonavir is contraindicated (see section 4.3).
Kombinacija avanafila i darunavira s niskom dozom ritonavira je kontraindicirana (vidjeti dio 4.3).
It is not recommended to co-administer boosted darunavir and boceprevir.
Ne preporučuje se istodobna primjena pojačanog darunavira i boceprevira.
Efficacy of darunavir 600 mg twice daily co-administered with 100 mg ritonavir twice daily in ARTexperienced patients
Djelotvornost darunavira od 600 mg dva puta na dan primijenjenog istodobno sa 100 mg ritonavira dva puta na dan u bolesnika prethodno liječenih ART-om
kidney or lung] - heart attack, slow heart beating, palpitations - visual disturbance - chills, feeling abnormal - a feeling of confusion or disorientation, altered mood, restlessness - fainting, epileptic fits, changes or loss of taste - mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue - running nose - skin lesions, dry skin - stiffness of muscles or joints, joint pain with or without inflammation - changes in some values of your blood cells or chemistry.
Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba) reakcija koja se naziva DRESS [teški osip, koji može biti praćen vrućicom, umorom, oticanjem lica ili limfnih čvorova, povišenjem eozinofila (vrsta bijelih krvnih stanica), učincima na jetru, bubreg ili pluća] srčani udar, spori otkucaji srca, osjećaj lupanja srca poremećaj vida zimica, nenormalno osjećanje osjećaj smetenosti ili dezorijentacije, promijenjeno raspoloženje, nemir nesvjestica, epileptički napadaji, promjene ili gubitak okusa ranice u ustima, povraćanje krvi, upala usnica, suhe usnice, obložen jezik curenje nosa oštećenja kože, suha koža ukočenost mišića ili zglobova, bolovi u zglobovima s ili bez upale promjene nekih vrijednosti stanica ili kemijskih nalaza u Vašoj krvi.
HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔* * Using cross-study comparisons to historical pharmacokinetic data
LIJEKOVI KOJI DJELUJU NA HIV Inhibitori prijenosa lanca integraze Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓ 38% dolutegravir Cmax ↓ 11% darunavir ↔*
These active substances include e.g.: - alfuzosin - amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine - astemizole, terfenadine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Te djelatne tvari, primjerice uključuju: - alfuzozin - amiodaron, bepridil, dronedaron, ivabradin, kinidin, ranolazin - astemizol, terfenadin - kolhicin kada se primjenjuje kod bolesnika s oštećenjem bubrega i/ili jetre (vidjeti dio 4.5) - ergot derivate (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin) - elbasvir/grazoprevir - cisaprid - dapoksetin - domperidon - naloksegol - lurasidon, pimozid, kvetiapin, sertindol (vidjeti dio 4.5) - triazolam, peroralno primijenjen midazolam (mjere opreza za parenteralnu primjenu midazolama, vidjeti dio 4.5) - sildenafil - kada se primjenjuje za liječenje plućne arterijske hipertenzije, avanafil - simvastatin, lovastatin i lomitapid (vidjeti dio 4.5) - dabigatran, tikagrelor (vidjeti dio 4.5).
No dose adjustment is required for darunavir/ritonavir in patients with renal impairment (see sections 4.4 and 5.2).
U bolesnika s oštećenjem bubrega nije potrebna prilagodba doze darunavira/ritonavira (vidjeti dijelove 4.4 i 5.2).